Evidence map›Paper›PMID 40093211›Full record

ArticlemedRxiv : the preprint server for health sciences2025

New Gain-of-Function Mutations Prioritize Mechanisms of HER2 Activation.

Christopher J Giacoletto, Liz J Valente, Lancer Brown, Sara Patterson, Rewatee Gokhale, Susan M Mockus, Wayne W Grody, Hong-Wen Deng, Jerome I Rotter, Martin R Schiller

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Christopher J GiacolettoHeligenics Inc., 10530 Discovery Dr., Las Vegas, NV 89135 USA.
Liz J ValenteHeligenics Inc., 10530 Discovery Dr., Las Vegas, NV 89135 USA.
Lancer BrownHeligenics Inc., 10530 Discovery Dr., Las Vegas, NV 89135 USA.
Sara PattersonThe Jackson Laboratory for Genomic Medicine, 10 Discovery Dr., Farmington, CT 06032.
Rewatee GokhaleThe Jackson Laboratory for Genomic Medicine, 10 Discovery Dr., Farmington, CT 06032.
Susan M MockusBaylor Genetics, 2450 Holcombe Blvd, Houston, TX, 77021.
Wayne W GrodyUCLA School of Medicine, Los Angeles, CA 90095 USA.
Hong-Wen DengTulane Center for Biomedical Informatics and Genomics, Department of Deming Department of Medicine, Tulane University, New Orleans, 70112 USA.
Jerome I RotterHeligenics Inc., 10530 Discovery Dr., Las Vegas, NV 89135 USA.
Martin R SchillerHeligenics Inc., 10530 Discovery Dr., Las Vegas, NV 89135 USA.

Funding

High Content Screening for Bifunctional Chimera BiologicsR44AI188872 · NIAID · HELIGENICS INC · PI LIZ VALENTE · 2025 to 2026
$1.6M
High-throughput functional analysis and clinical relevance of all possible variants of a geneR43HG012537 · NHGRI · HELIGENICS INC · PI SCHILLER, MARTIN R. · 2023 to 2023
$399k
NHGRI NIH HHS R43 HG012537NIAID NIH HHS R44 AI188872
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

cancerERBB2genomics Juxtamembrane regionGigaAssayHER2heterodimermutationpatient survival

Identifiers

PMID40093211
PMCPMC11908269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.